Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Written informed consent for the prospective cohort

  * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.
  * High-risk sarcoma definition:

    * Greater than 5cm or Grade 3
    * Deep anatomic location
  * Have disease amenable to biopsy

    o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study
  * Resectable tumour
  * Measurable disease by RECIST 1.1
  * Aged ≥ 18 years
  * WHO performance status 0-2
  * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy
  * Patients medically fit enough to undergo surgical resection
  * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule
  * Patients may also participate in the STRASS 2 trial

Exclusion Criteria:

-Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.

* Known additional malignancy that is progressing or requires active treatment
* Metastatic disease not amenable to curative intent local therapy
* Any active uncontrolled medical conditions